Isoflavonoids seem to have positive activity on human cardiovascular health. One of the reasons can be their antiplatelet potential.
In this study, we tested a series of structurally related isoflavonoids and we have shown that one of them, tectorigenin, has, at least, in ex vivo, conditions better antiplatelet effect than clinically used acetylsalicylic acid. The mechanism of action was also tested.